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Abstract. Recent studies in basic immunology have been directed towards the under- 
standing of the mechanism of T cell activation. T cells can be activated to proliferate via 
 the classical pathway through the antigen receptor (CD3-Ti) or via the alternate pathway 
through the CD2 receptor. Since immunologic unresponsiveness in lepromatous leprosy is 
considered to be due to the inability of T cells to proliferate upon stimulation, we have  
been interested in the nature of these receptors and the activation pathways in lympho- 
cytes of leprosy patients. In the present investigation we demonstrate: (i) CD2 receptor (E-
receptor) is downregulated in bacterial index positive lepromatous leprosy patients. (ii) The 
alternate pathway of T cell activation is impaired in lepromatous patients as revealed by  
the inability of their lymphocytes to proliferate in response to a pair of mitogenic anti-CD2 
monoclonals. (iii) The addition of recombinant interleukin 2 in vitro restores the ability of 
lymphocytes from lepromatous patients to proliferate in response to anti-CD2 antibodies. 
(iv) Interestingly, CD2 modulation and the associated functional impairment could be  
brought about in peripheral blood lymphocytes from normal subjects by prior treatment  
with Mycobacterium leprae in vitro. This approach would be useful in understanding the 
molecular events leading to the defective T cell functions in leprosy. 
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Introduction 
 
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. One  
population of leprosy patients, referred to as lepromatous type (LL), is known to  
have reduced T cell functions as evidenced by in vitro and in vivo tests (Nath et al.,  
1977; Godal, 1978). Though several approaches (Bloom and Mehra, 1984; Kaplan  
and Cohn, 1985; Nath et al., 1984) have been used in attempts to understand the 
mechanism of immunologic unresponsiveness in lepromatous leprosy (LL) patients,  
none has yet gained wide acceptance. 
Earlier studies indicated that the number of T cells, as enumerated by sheep
erythrocyte-rosette forming cell (E-RFC) assay (Dwyer et al., 1973; Nath et al., 1977; 
Jaswaney et al., 1980), was reduced in LL patients· Subsequently, when monoclonal 
antibody to a pan-T-cell marker (CD3) was used with the immunofluorescence  
technique, the proportion of T cells was found to be normal (Bach et al., 1981;  
Mshana et al., 1982). We have recently repeated these experiments and found that,  
while the proportion of CD3-positive cells was normal, E-receptor (CD2) positive  
cells were significantly reduced in LL patients (Muthukkaruppan et al., 1987). On  
the basis of our findings in conjunction with the role of CD2 receptor in T cell 
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biology (Springer et al., 1987), we have proposed a hypothesis to explain the  
mechanism of immunologic unresponsiveness in leprosy (Muthukkaruppan, 1986). 
Our earlier studies (Muthukkaruppan et al., 1987) have clearly demonstrated that
(i) the expression of CD2 receptor, but not that of CD3, was downregulated in  
bacillary index positive LL (LLBI + ) patients, (ii) this downregulation was strongly 
associated with reduced proliferative response to mitogens and antigens, and  
(iii) CD2 modulation and the associated immunosuppression could be brought  
about even in lymphocytes from normal subjects by prior incubation with M. leprae 
(Dharmendra lepromin) in vitro. 
CD2 receptor is expressed on all T cells (Kamoun et al., 1981). Certain mono- 
clonal antibodies to T111 epitope of'CD2 receptor were shown to downregulate T  
cell proliferation by blocking the production of interleukin 2(IL2) (Palacios and  
Martinez-Maza, 1982; Tadmori et al., 1985; Gromo et al., 1987). On the other hand, 
pairwise combinations of anti-CD2 monoclonal antibodies to certain other epitopes  
(T112 and T113, or T111 and D66) can induce T cells to proliferate (Meuer et al.,  
1984; Brottier et al., 1985). CD2 receptor also helps in thymocyte-thymic epithelial 
interaction (Singer and Haynes, 1987). These findings suggest that CD2 can  
function in activation signalling (alternate pathway of T cell activation) as well as in  
cell-to-cell adhesion. 
The present study was directed at understanding the nature of the alternate  
pathway of T cell activation in leprosy. Our data indicate that the alternate  
pathway of T cell activation is impaired in lymphocytes of LL patients as a result of  
CD2 modulation by M. leprae and this impairment in proliferation is due to a  
block in IL2 secretion. 
 
Materials and methods 
 
Patients 
 
A total of 19 lepromatous and 8 tuberculoid leprosy patients who were attending
Arogya Agam, Leprosy Hospital, Andipatty, were studied. These patients were
graded by Ridley-Jopling classification (Ridley and Jopling, 1966) on the basis of 
bacillary smears and clinical symptoms. The LL patients were subdivided into  
LLBI + i.e. those who demonstrated acid-fast bacilli in slit-skin smears, and baci- 
llary negative (LLBI–) patients. Most of the patients were undergoing multi-drug  
therapy. Control subjects were healthy volunteers from the university campus. 
 
Mycobacterial preparations 
 
Dharmendra lepromin was kindly provided by Dr U. Sengupta, Central JALMA  
Institute for Leprosy, Agra. Bacille Calmette-Guerin (BCG) was obtained from  
BCG Vaccine Laboratories, Madras, and subjected to treatment similar to the  
preparation of Dharmendra lepromin (Sengupta et al., 1978). 
 
Indirect immunofluorescence assay 
 
The percentages of CD2+ and CD3+ cells were enumerated as already described 
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(Muthukkaruppan et al., 1987). To 1×106 peripheral blood lymphocytes (PBL) in  
100 µl of medium monoclonal antibodies OKT3 (for CD3) and OKT11 (for CD2)
(Orthodiagnostic Inc., USA) were added and the cell suspensions incubated at 4°C  
for 30 min with frequent mixing. After washing the cells in RPMI 1640 (Sigma),  
50 µl of goat anti-mouse IgG FITC conjugate (Coulter Electronics) were added and  
the tubes were incubated at 4°C for 30 min. The percentage of fluorescence-positive  
cells was determined by phase contrast/fluorescence microscopy, counting 200 cells  
per tube. Ascites fluid (BRL) was used as control for monoclonal antibodies. 
To study the effect of M. leprae on the modulation of CD2, 1×106 PBL from
healthy non-contacts were incubated at 37°C for 24 h with Dharmendra lepromin 
containing 3×105 bacilli. As a control, PBL from the same individuals were treated  
with the same number of BCG separately. After this treatment cells were washed  
and stained for the detection of CD3 and CD2 receptors. 
 
Lymphocyte transformation test 
 
Triplicate cultures of PBL from leprosy patients were prepared in flat-bottom 96-  
well culture plates (Greiner, FRG) and cells were stimulated with optimal concen- 
tration of phytohaemoagglutinin-M (Bacto, USA) or monoclonal antibodies T111  
and D66 (a kind gift from Dr Alain Bernard, France) either alone or together as  
previously described (Brottier et al., 1985). In another set of cultures, PBL from  
healthy non-contacts were pretreated with M. leprae or BCG (1×105 bacilli per  
well at 37°C for 24 h) before adding mitogen or antibodies. 
 
Addition of recombinant IL2 
 
Recombinant IL2 (rIL2), a kind gift of Dr Sinigaglia, Hoffman La Roche, Basel,  
Switzerland, was added at 50 units per ml to cultures, wherever mentioned. 
 
Statistics 
 
Statistical comparisons were made by Student's t test. 
 
 
Results 
 
Alternate pathway of T cell activation in leprosy 
 
We have used a pair of mitogenic anti-CD2 monoclonal antibodies (T111 and D66)  
to elucidate the proliferative response of lymphocytes via the alternate pathway of  
T cell activation (figure 1). PBL from healthy non-contacts exhibited a good proli- 
ferative response. However, only a minimal response (SI 7·7±2·8) was observed in  
LLBI + patients, in contrast to the response in borderline tuberculoid and LLBI–  
patients. Comparable results were obtained when PHA-M was used as a stimulant. 
Indirect immunofluorescence assay with PBL from the above subjects revealed a 
significant reduction in the proportion of CD2-positive cells only in LLBI+
patients (figure 1). These results indicate that the alternate pathway of T cell  
activation is impaired in LLBI+ patients and that this is correlated with the  
modulation of CD2 receptor. 
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Figure 1. Impairment of alternate pathway of T cell proliferation in leprosy in correlation 
with CD2 modulation. Figures in parentheses below the histograms are numbers of indi- 
viduals studied. HNC, Healthy non-contacts; BT, borderline tuberculoid. aPercentages of 
immunofluorescence-positive cells ± SE; bP <0·001 between stimulation indices (SI) of 
LLBI + (BI ranging from 0·4–6) and LLBI– patients; cP<0·001 between CD2-positive
and CD3-positive cells. 
 
Effect of M. leprae on alternate pathway of T cell activation in PBL of healthy non-
contacts 
 
The reduction in the proportion of CD2-positive cells was found in LLBI+  
patients, i.e. in persons harbouring M. leprae in vivo. We therefore wanted to  
determine the effect of M. leprae on PBL of healthy non-contacts. For this purpose  
we have developed an in vitro test in which PBL from healthy non-contacts were  
treated with M. leprae or BCG and the expression of CD2 and CD3 receptors was 
analysed. As shown in table 1, M. leprae, but not BCG, significantly modulated the 
 
Table 1. Percentage of CD2-positive and CD3-
positive cells in normal PBL treated with M. leprae
or BCG· 
 
aNumber of subjects 5 in each group. 
bCells were stained with monoclonal antibodies 
OKT11 for CD2 and OKT3 for CD3. The data are 
mean ± SE. 
c P< 0·001 between untreated and M. leprae treated 
groups in CD2-positive cells. 
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expression of the CD2 receptor, while the percentage of CD3-positive cells remained 
unaltered. In parallel experiments, PBL from the healthy subjects were incubated  
with M. leprae or BCG for 24h and then stimulated with a pair of anti-CD2  
antibodies (figure 2). The data clearly indicate impairment of the alternate pathway
 
Figure 2. Impairment of alternate pathway of T cell proliferation in PBL of healthy non- 
contacts by M. leprae in vitro. aIL2 and/or T111+D66 were added to untreated PBL 
cultures or cultures pretreated for 24 h with M. leprae/BCG; bP<0·001 between cpm of 
M. leprae treated and untreated cultures stimulated with T111+D66; cP<0·001 between
cpm of M. leprae treated cultures stimulated with T111+D66 with and without the 
addition of rIL2; dP<0·001 between cpm of M. leprae and BCG treated cultures 
stimulated with T111 + D66. 
 
 
of T cell activation as a result of CD2 modulation. The response to PHA-M was  
also suppressed by M. leprae, as shown in figure 3.
 
Recovery of proliferative response by the addition of rIL2 
 
We next examined the mechanism of unresponsiveness produced by M. leprae  
through CD2 modulation. Table 2 shows that the addition of rIL2 (50 U/ml) could  
restore the proliferative response to the pair of anti-CD2 antibodies in PBL of  
LLBI + patients. Further, M. leprae pretreated PBL from healthy non-contacts also 
showed recovery of the proliferative response to anti-CD2 antibodies upon the  
addition of rIL2 (figure 2). Interestingly, very little proliferative response to  
M. leprae antigens was observed in cultures of normal PBL even with the addition  
of rIL2 (figure 2).
 
 
Discussion 
 
Several studies have clearly demonstrated that the cell-mediated immune response 
is suppressed in LL patients (Godal, 1978; Nath, 1983; Bloom and Mehra, 1984). 
Peripheral blood T cells from these patients were unable to proliferate in response 
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Figure 3. Impairment of proliferative response to PHA-M in PBL of healthy non- 
contacts by M. leprae in vitro. aIL2 and/or PHA-M were added to PBL untreated  
cultures or cultures pretreated for 24 h with M. leprae/BCG; bΡ<0·001 between SI of  
M. leprae treated and untreated cultures stimulated with PHA-M; cP<0·001 between SI  
of M. leprae treated cultures stimulated with PHA-M with and without the addition of  
rIL2. 
 
Table 2. Recovery of proliferative response via alternate
pathway by the addition of rIL2 to LLBI + PBL cultures.
 
aAt the time of study, the bacillary index of the patients ranged
between 0·4 and 5. The percentage of CD2-positive and CD3-
positive cells were 46·0±1·8 and 62·2±2·6 respectively
(P< 0·001). 
 
 
to M. leprae. This was suggested to be due to reduced IL2 production and IL2  
receptor expression (Nath et al., 1984; Kaplan and Cohn, 1985; Mohagheghpour  
et al., 1985). We have initiated a new approach to explain the mechanism of  
M. leprae specific unresponsiveness in leprosy (Muthukkaruppan, 1986). 
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The CD2 receptor was found to be significantly downregulated in LLBI+  
patients and this condition was strongly associated with impaired proliferative
response to PHA-M and PPD (Muthukkaruppan et al., 1987). The modulation of  
CD2 and the associated impairment of T cell proliferation can be brought about
even in lymphocytes from normal subjects by prior incubation with M. leprae 
(Dharmendra lepromin) in vitro (Muthukkaruppan et al., 1987). It is of interest to  
note that tuberculoid leprosy, though caused by the same bacteria, did not show  
reduction in the proportion of CD2-positive cells in the peripheral blood circula- 
tion (Nath et al., 1977; Muthukkaruppan et al., 1987). This means that the CD2 
modulation would require the presence of a certain detectable level of bacilli, as in  
LLBI+ patients. 
Our more recent study (Muthukkaruppan et al., 1988) indicates that the CD3
receptor, though apparently expressed in normal proportion in the peripheral blood  
of LLBI+ patients, is functionally impaired, since CD2 modulated T cells did not 
proliferate in response to mitogenic anti-CD3 monoclonal antibody. The data  
presented here demonstrate the functional impairment of the alternate pathway  
(CD2) of T cell proliferation, since PBL from LLBI+ patients were unable to proli- 
ferate in response to a pairwise combination of anti-CD2 monoclonal antibodies  
(figure 1). Thus, both classical (CD3) and alternate (CD2) pathways of T cell acti- 
vation are impaired as a result of CD2 modulation. Further, proliferative response  
to M. leprae could not be recovered even by the addition of IL2. However, when  
such T cells were activated by a potent stimulus like PHA-M or a pair of anti-CD2 
monoclonals vigorous proliferation ensued only when exogenous IL2 was present in  
the cultures (figures 2 and 3). 
Accumulating evidence in recent years suggests the importance of a functional
interrelationship between CD2 and CD3 receptor complexes in T cell activation 
(Breitmeyer, 1987). T cells after treatment with certain anti-CD2 monoclonals were 
unable to proliferate in response to mitogenic anti-CD3 antibodies. Furthermore,  
the importance of interaction between CD2 receptor and its natural ligand, lym- 
phocyte function associated antigen 3 (LFA3), in T cell functions has been empha- 
sized (Krensky et al., 1983; Springer et al., 1987). In the light of these findings, the 
present study may suggest the importance of CD2 modulation in unresponsiveness  
in leprosy. However, further investigations are required to understand the mecha- 
nism of CD2 modulation by M. leprae as well as the nature of CD2 and IL2  
receptor expression in LLBI + patients. 
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